Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles

Biomaterials

Volumn 35, Issue 11, 2014, Pages 3641-3649

  Su, Fang Yi ^a   Chuang, Er Yuan ^a   Lin, Po Yen ^a   Chou, Yi Chun ^a   Chen, Chiung Tong ^b   Mi, Fwu Long ^c   Wey, Shiaw Pyng ^d   Yen, Tzu Chen ^e   Lin, Kun Ju ^d,e   Sung, Hsing Wen ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Biodistribution; Chemotherapy induced neutropenia; Glucose utilization; Oral protein delivery; Translational medicine

Indexed keywords

BIODISTRIBUTION; CHEMOTHERAPY-INDUCED NEUTROPENIA; GLUCOSE UTILIZATION; ORAL PROTEIN DELIVERY; TRANSLATIONAL MEDICINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CHITOSAN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLUCOSE; GRANULOCYTE COLONY-STIMULATING FACTOR; HYDROGEN-ION CONCENTRATION; INTESTINES; NANOPARTICLES; NEUTROPENIA; PARTICLE SIZE; PENTETIC ACID; POLYGLUTAMIC ACID; POSITRON-EMISSION TOMOGRAPHY; PROTEOLYSIS; RATS; RATS, WISTAR; STATIC ELECTRICITY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84895056704     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.01.020     Document Type: Article

References (48)

1. Trillet-Lenoir V., Green J., Manegold C., Von Pawel J., Gatzemeier U., Lebeau B., et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993, 29A:319-324.
2. Welte K., Gabrilove J., Bronchud M.H., Platzer E., Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996, 88:1907-1929.
3. Layton J.E., Hall N.E. The interaction of G-CSF with its receptor. Front Biosci 2006, 11:3181-3189.
4. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. JClin Oncol 2006, 24:3187-3205.
5. Hamman J.H., Enslin G.M., Kotze A.F. Oral delivery of peptide drugs: barriers and developments. Biodrugs 2005, 19:165-177.
6. Morishita M., Peppas N.A. Is the oral route possible for peptide and protein drug delivery?. Drug Discov Today 2006, 11:905-910.
7. Su F.Y., Lin K.J., Sonaje K., Wey S.P., Yen T.C., Ho Y.C., et al. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 2012, 33:2801-2811.
8. Dodane V., Amin Khan M., Merwin J.R. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999, 182:21-32.
9. Bernkop-Schnürch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. JControl Release 1998, 52:1-16.
10. Citi S. Protein kinase inhibitors prevent junction dissociation induced by low extracellular calcium in MDCK epithelial cells. JCell Biol 1992, 117:169-178.
11. Bai Y., Ann D.K., Shen W.C. Recombinant granulocyte colony-stimulating factor-transferrin fusion protein as an oral myelopoietic agent. Proc Natl Acad Sci U S A 2005, 102:7292-7296.
12. Dale D.C., Liles W.C., Summer W.R., Nelson S. Review: granulocyte colony-stimulating factor-role and relationships in infectious diseases. JInfect Dis 1995, 172:1061-1075.
13. Bernkop-Schnürch A., Paikl C., Valenta C. Novel bioadhesive chitosan-EDTA conjugate protects leucine enkephalin from degradation by aminopeptidase N. Pharm Res 1997, 14:917-922.
14. Sonaje K., Lin Y.H., Juang J.H., Wey S.P., Chen C.T., Sung H.W. Invivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009, 30:2329-2339.
15. Evans D.F., Pye G., Bramley R., Clark A.G., Dyson T.J., Hardcastle J.D. Measurement of gastrointestinal pH profiles in normal ambulant human-subjects. Gut 1988, 29:1035-1041.
16. Gharahdaghi F., Weinberg C.R., Meagher D.A., Imai B.S., Mische S.M. Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis 1999, 20:601-605.
17. Hara K., Suda T., Suda J., Eguchi M., Ihle J.N., Nagata S., et al. Bipotential murine hemopoietic cell line (NFS-60) that is responsive to IL-3, GM-CSF, G-CSF, and erythropoietin. Exp Hematol 1988, 16:256-261.
18. Moosavi M.A., Yazdanparast R., Lotfi A. GTP induces S-phase cell-cycle arrest and inhibits DNA synthesis in K562 cells but not in normal human peripheral lymphocytes. JBiochem Mol Biol 2006, 39:492-501.
19. Uemura Y., Kobayashi M., Nakata H., Harada R., Kubota T., Taguchi H. Effect of serum deprivation on constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells. Int J Cancer 2004, 109:826-832.
20. Gomes C.M., Abrunhosa A.J., Ramos P., Pauwels E.K.J. Molecular imaging with SPECT as a tool for drug development. Adv Drug Deliv Rev 2011, 63:547-554.
21. Sonaje K., Lin K.J., Wey S.P., Lin C.K., Yeh T.H., Nguyen H.N., et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials 2010, 31:6849-6858.
22. Teply B.A., Tong R., Jeong S.Y., Luther G., Sherifi I., Yim C.H., et al. The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules. Biomaterials 2008, 29:1216-1223.
23. Shimamura M., Kobayashi Y., Yuo A., Urabe A., Okabe T., Komatsu Y., et al. Effect of human recombinant granulocyte colony-stimulating factor on hematopoietic injury in mice induced by 5-fluorouracil. Blood 1987, 69:353-355.
24. Horiguchi J., Rai Y., Tamura K., Taki T., Hisamatsu K., Ito Y., et al. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan. Anticancer Res 2009, 29:625-630.
25. Kimura A., Rieger M.A., Simone J.M., Chen W., Wickre M.C., Zhu B.M., et al. The transcription factors STAT5A/B regulate GM-CSF-mediated granulopoiesis. Blood 2009, 114:4721-4728.
26. Murata Y., Kubota K., Yukihiro M., Ito K., Watanabe H., Shibuya H. Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT. Nucl Med Biol 2006, 33:999-1004.
27. Kapoor V., McCook B.M., Torok F.S. An introduction to PET-CT imaging. Radiographics 2004, 24:523-543.
28. Chuang E.Y., Nguyen G.T., Su F.Y., Lin K.J., Chen C.T., Mi F.L., et al. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT. Biomaterials 2013, 34:7994-8001.
29. Aapro M.S., Bohlius J., Cameron D.A., Dal Lago L., Donnelly J.P., Kearney N., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011, 47:8-32.
30. Han Y., Yu Z., Wen S., Zhang B., Cao X., Wang X. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Res Treat 2012, 131:483-490.
31. Sheridan W.P., Morstyn G., Wolf M., Dodds A., Lusk J., Maher D., et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989, 2:891-895.
32. Scholz M., Engel C., Apt D., Sankar S.L., Goldstein E., Loeffler M. Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats. Cell Prolif 2009, 42:823-837.
33. Allen A., Flemstrom G., Garner A., Kivilaakso E. Gastroduodenal mucosal protection. Physiol Rev 1993, 73:823-857.
34. Sung H.W., Sonaje K., Liao Z.X., Hsu L.W., Chuang E.Y. pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications. Acc Chem Res 2012, 45:619-629.
35. Holtmann G., Kelly D.G., Sternby B., DiMagno E.P. Survival of human pancreatic enzymes during small bowel transit: effect of nutrients, bile acids, and enzymes. Am J Physiol 1997, 273. G553-8.
36. Legen I., Kristl A. Factors affecting the microclimate pH of the rat jejunum in ringer bicarbonate buffer. Biol Pharm Bull 2003, 26:886-889.
37. Layer P., Go V.L., DiMagno E.P. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am J Physiol 1986, 251:G475-G480.
38. Yin L., Ding J., He C., Cui L., Tang C., Yin C. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 2009, 30:5691-5700.
39. Feng Y., Klein B.K., McWherter C.A. Three-dimensional solution structure and backbone dynamics of a variant of human interleukin-3. JMol Biol 1996, 259:524-541.
40. Adson A., Burton P.S., Raub T.J., Barsuhn C.L., Audus K.L., Ho N.F. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. JPharm Sci 1995, 84:1197-1204.
41. Chuang E.Y., Lin K.J., Su F.Y., Mi F.L., Maiti B., Chen C.T., et al. Noninvasive imaging oral absorption of insulin delivered by nanoparticles and its stimulated glucose utilization in controlling postprandial hyperglycemia during OGTT in diabetic rats. JControl Release 2013, 172:513-522.
42. Kwon K.C., Verma D., Singh N.D., Herzog R., Daniell H. Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv Drug Deliv Rev 2013, 65:782-799.
43. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
44. Welte K. Discovery of G-CSF and early clinical studies. Twenty years of G-CSF 2012, 15-24. Springer Basel. G. Molineux, M. Foote, T. Arvedson (Eds.).
45. Jamar F., Field C., Leners N., Ferrant A. Scintigraphic evaluation of the haemopoietic bone marrow using a 99mTc-anti-granulocyte antibody: a validation study with 52Fe. Br J Haematol 1995, 90:22-30.
46. Kazama T., Faria S.C., Varavithya V., Phongkitkarun S., Ito H., Macapinlac H.A. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005, 25:191-207.
47. Ho K.C., Lin G., Wang J.J., Lai C.H., Chang C.J., Yen T.C. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging 2009, 36:200-208.
48. Sugawara Y., Fisher S.J., Zasadny K.R., Kison P.V., Baker L.H., Wahl R.L. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. JClin Oncol 1998, 16:173-180.